US Patent

US9228187 — Antisense molecules and methods for treating pathologies

Composition of Matter · Assigned to University of Western Australia · Expires 2030-11-12 · 4y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects antisense molecules that can bind to a specific target site in the dystrophin gene to induce exon skipping.

USPTO Abstract

An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.

Drugs covered by this patent

Patent Metadata

Patent number
US9228187
Jurisdiction
US
Classification
Composition of Matter
Expires
2030-11-12
Drug substance claim
Yes
Drug product claim
Yes
Assignee
University of Western Australia
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.